Jushi Holdings Inc (JUSHF)
0.70
-0.02
(-2.79%)
USD |
OTCM |
May 17, 15:59
Jushi Holdings Revenue (Quarterly): 65.46M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 65.46M |
| December 31, 2023 | 67.77M |
| September 30, 2023 | 65.38M |
| June 30, 2023 | 66.42M |
| March 31, 2023 | 69.87M |
| December 31, 2022 | 76.82M |
| September 30, 2022 | 72.82M |
| June 30, 2022 | 72.76M |
| March 31, 2022 | 61.89M |
| December 31, 2021 | 65.89M |
| September 30, 2021 | 53.98M |
| Date | Value |
|---|---|
| June 30, 2021 | 47.74M |
| March 31, 2021 | 41.68M |
| December 31, 2020 | 32.29M |
| September 30, 2020 | 24.91M |
| June 30, 2020 | 14.93M |
| March 31, 2020 | 8.633M |
| December 31, 2019 | 6.034M |
| September 30, 2019 | 3.588M |
| June 30, 2019 | 0.2264M |
| March 31, 2019 | 0.3807M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.2264M
Minimum
Jun 2019
76.82M
Maximum
Dec 2022
45.96M
Average
57.93M
Median
Revenue (Quarterly) Benchmarks
| Anika Therapeutics Inc | 40.52M |
| Spero Therapeutics Inc | 71.82M |
| scPharmaceuticals Inc | 6.102M |
| electroCore Inc | 5.443M |
| NovaBay Pharmaceuticals Inc | 2.631M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -18.36M |
| Total Expenses (Quarterly) | 61.34M |
| EPS Diluted (Quarterly) | -0.09 |
| Enterprise Value | 321.99M |
| Gross Profit Margin (Quarterly) | 49.39% |
| Profit Margin (Quarterly) | -28.04% |
| Earnings Yield | -51.43% |
| Operating Earnings Yield | 9.07% |
| Normalized Earnings Yield | -44.45 |